We are live on ! Find out more
BOLT icon

Bolt Biotherapeutics

71 hedge funds and large institutions have $449M invested in Bolt Biotherapeutics in 2021 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 29 increasing their positions, 11 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

164% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 11

157% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 7

16% more funds holding

Funds holding: 6171 (+10)

0.19% more ownership

Funds ownership: 4.58%4.77% (+0.19%)

13% less capital invested

Capital invested by funds: $514M → $449M (-$64.6M)

20% less funds holding in top 10

Funds holding in top 10: 54 (-1)

Holders
71
Holders Change
+10
Holders Change %
+16.39%
% of All Funds
1.24%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.07%
New
18
Increased
29
Reduced
11
Closed
7
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Prudential Financial
76
Prudential Financial
New Jersey
-$311K -1,005 Closed
Two Sigma Investments
77
Two Sigma Investments
New York
-$190K -614 Closed
TFO
78
Tarbox Family Office
California
-$15K -50 Closed

BOLT Hedge Fund Activity: Q3 2021 in Review

71 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q3 2021, worth a combined $449M — down 13% from $514M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new BOLT positions and 7 closed out — a net gain of 11 holders — while 29 added to existing stakes and 11 trimmed.

The largest buyer was Samlyn Capital, opening a new position worth an estimated $10.5M. The largest seller was Franklin Resources, exiting entirely with an estimated $2.32M sold.

  • 71 institutional investors held Bolt Biotherapeutics (BOLT) as of Q3 2021, up from 61 in Q2 2021.
  • Funds reported $449M of Bolt Biotherapeutics stock for Q3 2021, down 13% quarter-over-quarter.
  • 18 funds opened new Bolt Biotherapeutics positions in Q3 2021 and 7 closed out, a net change of +11 holders.
  • The largest Bolt Biotherapeutics buyer in Q3 2021 was Samlyn Capital, an estimated $10.5M added.
  • The largest Bolt Biotherapeutics seller in Q3 2021 was Franklin Resources, an estimated $2.32M sold.

Based on aggregated 13F filings for Q3 2021.